Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.
LowReport
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses [Yahoo! Finance]
LowReport
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses [Yahoo! Finance]
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
LowReport
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: